-
Mashup Score: 253Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment - 15 hour(s) ago
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers. Most people with MASLD die from cardiac-related causes. This outcome is attributed to the shared pathogenesis of MASLD and cardiometabolic diseases, involving unhealthy dietary habits, dysfunctional adipose tissue, insulin resistance, and subclinical inflammation.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2The promise and hope of GLP-1 receptor agonists - 2 day(s) ago
GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood glucose and bodyweight. Several agents in the GLP-1 receptor agonist class have been shown to reduce the risk of major adverse cardiovascular events (MACE) and the progression of chronic kidney disease in people with type 2 diabetes.1 Moreover, in 2023, the SELECT trial2 found that 2·4 mg semaglutide per week reduced MACE by 20% over a mean period of 3·3 years in people with pre-existing cardiovascular disease and overweight or obesity but without type 2 diabetes.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Priya Sumithran & Jamy Ard comment on: https://t.co/XSJnLfQWU3 The promise and hope of #GLP-1 receptor agonists #T2D #CVD #kidney
-
-
Mashup Score: 47Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials - 2 day(s) ago
We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Effects of #GLP-1 receptor agonists on #kidney and #cardiovascular disease outcomes: a meta-analysis of randomised controlled trials https://t.co/aVZ4Kcd3Bb #T2D #CVD
-
-
Mashup Score: 37Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions - 2 day(s) ago
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Estimating direct tissue effects versus weight loss effects of #incretin-based drugs for #obesity on various chronic conditions https://t.co/vjdHEUm5Ei #weightloss #GLP-1 receptor agonists
-
-
Mashup Score: 135
The hypothalamic–pituitary–thyroid axis plays a crucial role in the pathogenesis, diagnosis, risk stratification, effectiveness of radioiodine therapy, and treatment response evaluation in epithelial thyroid cancer. Supraphysiological doses of levothyroxine are used in patients with intermediate-risk and high-risk thyroid cancer to suppress thyroid-stimulating hormone (TSH) to prevent tumour progression. However, free thyroxine and tri-iodothyronine have also been found to promote tumour growth in thyroid cancer preclinical models.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—The role of the hypothalamic–pituitary–thyroid axis in #thyroid #cancer https://t.co/sjaMcRYzoP #HPT axis #thyroidcancer https://t.co/9XkgeZSxYl
-
-
Mashup Score: 2Protein-binding therapy: a new approach to lower cholesterol - 2 day(s) ago
Homozygous familial hypercholesterolaemia affects approximately 30 000 individuals worldwide.1,2 Patients have untreated high plasma LDL cholesterol over 10 mmol/L; physical signs include arcus cornealis, xanthelasmas, skin and tendon xanthomas, and markedly elevated risk of premature atherosclerotic cardiovascular disease and aortic valve disease.2 Inheritance is semi-dominant, meaning that parents who are heterozygous also have hypercholesterolaemia, albeit milder than their children with homozygous familial hypercholesterolaemia.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Linked Comment by Robert A Hegele: Protein-binding therapy: a new approach to lower cholesterol https://t.co/nXK6AjdQIw #familial hypercholesterolaemia #HoFH #LDL #cholesterol #lerodalcibep
-
-
Mashup Score: 17
The LDL cholesterol response was highly variable, but generally similar in patients treated with both lerodalcibep and evolocumab. Importantly, the study showed the inability to predict response based on genotyping, reinforcing the rationale for PCSK9 inhibition in all patients with homozygous familial hypercholesterolemia and continuing its use in responders.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Lerodalcibep and evolocumab for the treatment of #homozygous #familial #hypercholesterolaemia with #PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial https://t.co/Fxm5FRp6jb #HoFH #LDL #cholesterol #lerodalcibep
-
-
Mashup Score: 31
Osteoporotic fractures are a major health challenge in older adults. Despite the availability of safe and effective therapies for osteoporosis, these therapies are underused in individuals at high risk for fracture, calling for better case-finding and fracture risk assessment strategies. Artificial intelligence (AI) and machine learning (ML) hold promise for enhancing identification of individuals at high risk for fracture by distilling useful features from high-dimensional data derived from medical records, imaging, and wearable devices.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—The potential role for artificial intelligence in #fracture risk prediction https://t.co/yzSqSvC4j5 #ArtificialIntelligence #AI #osteoporosis https://t.co/8jXU3Is1DV
-
-
Mashup Score: 58
Semaglutide 2·4 mg improved heart failure-related symptoms and physical limitations, and reduced bodyweight in patients with obesity-related HFpEF and type 2 diabetes, all independently of baseline HbA1c, and resulted in lower rates of hypoglycaemia than placebo, despite a well controlled baseline HbA1c and broad use of concomitant glucose-lowering medications.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Semaglutide in #obesity-related #heartfailure with preserved ejection fraction & type 2 #diabetes across baseline HbA1c levels (STEP-HFpEF DM): prespecified analysis of heart failure & metabolic outcomes from a randomised, placebo-controlled trial https://t.co/UdxryZxYwo #T2D
-
-
Mashup Score: 40Osteopenia: a key target for fracture prevention - 4 day(s) ago
Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has also had the quantitative meaning of a bone mineral density (BMD) T-score between –1·0 and –2·5. More than 60% of White women older than 64 years are osteopenic. Although fracture risk is often lower in osteopenic women than in those with osteoporosis, their greater number means that most fractures occur in osteopenic individuals. Fracture risk varies widely in the osteopenic range, depending on factors including BMD, age, fracture history, and nationality and ethnicity.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Osteopenia: a key target for fracture prevention https://t.co/xBTW4DsDAR #osteopenia #osteoporosis #BoneHealth #fractures https://t.co/TCHsU84nkN
-
New—Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment https://t.co/uViLbyUHVf #MASLD #OpenAccess https://t.co/Ld2MKCYhO9